PDL BioPharma — Jefferies 2016 Healthcare Conference
25 slides from PDL BioPharma's conference presentation, Jun 7, 2016

Slide 1: Jefferies 2016 Healthcare Conference
¢PDL BioPharma’ Jefferies 2016 Healthcare Conference June 7, 2016 =

Slide 2: Forward Looking Statements
Forward Looking Statements <3 This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. A

Slide 3: Overview of PDL BioPharma
¢PDL BioPharma’ OVERVIEW OF PDL BIOPHARMA

Slide 4: Company Overview
Company Overview <3 ¢ PDL BioPharma, Inc. (“PDL” or the “Company”) provides growth capital and financing solutions to late stage public and private healthcare companies. ¢ The Company offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. ¢ The

Slide 5: Key Information
Key Information a: 3 Ticker PDLI (NASDAQ) Location Incline Village, Nevada Employees 1 2015 Revenues $590 million 2015 Expenses $40 million 2G16 Quarterly: Dividend $0.05 /share on June 13 (Pay Date) 2Q16 Quarterly Dividend (Record Date) sune:S 2016 Dividend Policy Quarterly; set in second month of

Slide 6: Experienced Management and Board
Experienced Management and Board <3 Management Board of Directors John McLaughlin Paul Edick President & CEO David Gryska Christopher Stone F VP, General Counsel & Jody Lindell Secretary John McLaughlin Peter Garcia Samuel Saks VP & Chief Financial Officer Paul Sandman Danny Hart Harold E. Selick, P

Slide 7: Corporate Developments
¢PDL BioPharma’ CORPORATE DEVELOPMENTS

Slide 8: Recent Developments
Recent Developments <3 © Quarterly Dividend * Declared $0.05/share dividend payable on June 13 to shareholders of record on June 6. ¢ Ariad ¢ Restructured the agreement with Ariad to provide more flexibility for PDL. ¢ Previously, the agreement provided that Ariad was required to draw $50 million in

Slide 9: Noden Transaction
Noden Transaction <3 PDL has committed to an equity investment in Noden Pharma DAC (Noden), which is domiciled in Ireland. ¢ Investment is part of an acquisition of specialty pharma products. ¢ Equity used for asset acquisition and working capital. ¢ PDL will make equity investments to ultimately ha

Slide 10: Hypertension and Tekturna
Hypertension and Tekturna <3 ¢@ Hypertension * Chronic condition with serious long term cardiovascular and renal implications affecting about one-third of US adult population = 78 million people. ¢ Hypertension risk factors include stroke, heart attack, congestive heart failure and renal disease. ¢

Slide 11: Noden Transaction Short Term Timeline
Noden Transaction Short Term Timeline <3 Execution of documents ° May 24 ¢ Public announcement with summary of terms ¢ Hart-Scott-Rodino Filing ¢ Filed on May 31, 2016 ¢ FTC clearance typically requires 30 days but can be as short as 2-3 weeks « Expected Closing ¢ Late June 2016 ¢ Public announcemen

Slide 12: Noden Financial and Strategic Impact
Noden Financial and Strategic Impact <3 PDL will consolidate Noden financials. «Expected to be immediately accretive to cash earnings. Strong revenue impact on a consolidated basis. ¢Noden expected to have a lower effective tax rate than PDL. Provides a vehicle for additional product acquisitions.

Slide 13: Asset Overview
¢PDL BioPharma’ ASSET OVERVIEW

Slide 14: Income Generating Transactions - Current Investments
16 Income Generating Transactions <3 11 Current Investments Royalty Acquisition cela kaléo Pharmaceuticals, Inc. ARIAD seis sizes | | ea ssepes — ‘Senior Secured ‘Senior Secured Royalty Acquisition ‘Senior Secured Rovaty Transaction financing Financing financing Senior Secured Financing DIRECT FLO\

Slide 15: Acquired Income Generating Assets (1/2)
Acquired Income Generating Assets (1/2) <3 Entity Structure Technology Deal Summary Combination drug (sufentanil * $66 millon in exchange for 75 percent of the royalties AcelRx receives microtablet) and device product used from Griinenthal as well as 80 percent ofthe first four commercial AACCIRX Ro

Slide 16: Acquired Income Generating Assets (2/2)
Acquired Income Generating Assets (2/2) a: 3 Entity Structure Technology Deal Summary Transcatheter aortic valve systemto —* $35M loan at signing plus $15M loan funded in November 2014 treat aortic stenosis with minimal risk and $6 million loan funded in January 2016, secured by DIRECT FLO\ Debt of

Slide 17: Concluded Transactions — Performance Overview
Concluded Transactions — Performance Overview <3 Entity Structure Technology Deal Summary Commercialzation ofEnablex, a * $55M of Notes secured by assets of Merus. MERUS LABS Debt _tteatmentfor overactive bladder,and + In September 2013 Merus repaid PDL in full plus pre-paymenttees. Vaneocin, an int

Slide 18: Unapproved Queen Licensed Product
18 Unapproved Queen Licensed Product — Term and Royalty Rates 3 © Solanezumab ¢ Humanized antibody targeting beta amyloid, which is believed to cause Alzheimer's Disease, designed by PDL and being developed by Eli Lilly. ® Previous Phase 3s: Mild & Moderate Alzheimer's Disease ¢ In 2012, Lilly repor

Slide 19: Unapproved Queen Licensed Product
Unapproved Queen Licensed Product — Term and Royalty Rates 3 © New Phase 3: Mild Alzheimer's Disease ¢ Based on the results in its initial Phase 3 trials, Lilly commenced a new Phase 3 trial in patients with only mild Alzheimer's Disease in 2013. ¢ Study uses PET scans or similar screens to distingu

Slide 20: Financials
¢PDL BioPharma’ FINANCIALS

Slide 21: First Quarter Ended March 31, 2016
First Quarter Ended March 31, 2016 Overview Three Months Ended March 31, (in thousands, except per share amounts) 2016 2015 Royalties from Queen et al patents $ 121,455 $ 127,810 Royalty rights - change in fair value (27,102) 11,362 Interest revenue 8,964 License and other (193) - Total revenues: 10

Slide 22: Debt
¢PDL BioPharma’ DEBT

Slide 23: Current and Long-Term Debt
Current and Long-Term Debt <3 ¢@ On November 20, 2015, PDL repurchased approximately $53.6 million in aggregate principal amount of its 4.00% Convertible Senior Notes Due February 1, 2018 for approximately $43.0 million in cash in open market transactions. The closing of the transaction occurred on

Slide 24: Conclusion
¢PDL BioPharma’ CONCLUSION

Slide 25: Investment Highlights
Investment Highlights <3 Sixteen income generating deals to date deploying (including funds to be deployed in Noden transaction) over $1 billion in capital with potential for additional deals. ¢ Adverse equity and debt markets represent the most favorable environment for PDL as an alternative provid
Source: SEC EDGAR · 8-K filed Jun 7, 2016
More decks from PDL BioPharma Inc
Q3 2020 Earnings Presentation13 slides · Nov 13, 2020
Investor Presentation (September 2020)32 slides · Sep 10, 2020
Q2 2020 Earnings Presentation17 slides · Aug 6, 2020
Investor Presentation (July 2020)30 slides · Jul 17, 2020
Q1 2020 Earnings Presentation15 slides · May 7, 2020
Q4 2019 Earnings Presentation16 slides · Mar 11, 2020